Review Article

Design of ultra-stable insulin analogues for the developing world

Michael A. Weiss

Departments of Biochemistry, Biomedical Engineering and Medicine, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, Ohio, USA

ABSTRACT

The engineering of insulin analogues illustrates the application of structure-based protein design to clinical medicine. Such design has traditionally been based on structures of wild-type insulin hexamers in an effort to optimize the pharmacokinetic (PK) and pharmacodynamic properties of the hormone. Rapid-acting insulin analogues (in chronological order of their clinical introduction, Humalog® [Eli Lilly & Co.], Novolog® [Novo-Nordisk], and Apidra® [Sanofi-Aventis]) exploit the targeted destabilization of subunit interfaces to facilitate capillary absorption. Conversely, long-acting insulin analogues exploit the stability of the insulin hexamer and its higher-order self-assembly within the subcutaneous depot to enhance basal glycemic control. Current products either operate through isoelectric precipitation (insulin glargine, the active component of Lantus®; Sanofi-Aventis) or employ an albumin-binding acyl tether (insulin detemir, the active component of Levemir®; Novo-Nordisk). Such molecular engineering has often encountered a trade-off between PK goals and product stability. Given the global dimensions of the diabetes pandemic and complexity of an associated cold chain of insulin distribution, we envisage that concurrent engineering of ultra-stable protein analogue formulations would benefit the developing world, especially for patients exposed to high temperatures with inconsistent access to refrigeration. We review the principal mechanisms of insulin degradation above room temperature and novel molecular approaches toward the design of ultra-stable rapid-acting and basal formulations.

Keywords: Diabetes mellitus, nanotechnology, protein engineering, protein stability, protein degradation

INTRODUCTION

Elucidation of the crystal structure of the insulin hexamer in 1969 by the late Hodgkin DC *et al.*, was a landmark in structural biology [Figure 1].[1,2] The first depiction of a protein homo-oligomer and associated zinc (Zn) binding site, the three-dimensional structure of insulin continues to provide rich insight into multiple biological and pharmacologic processes, ranging from the biosynthesis and storage of insulin in pancreatic β-cells,[3] to analogue design to enhance the treatment of diabetes mellitus (DM).[4-6] Although academic

| Access this article online	
Quick Response Code:	**Website:** www.thejhs.org
	DOI: 10.4103/1658-600X.114683

Address for correspondence:
Dr. Michael A. Weiss, Departments of Biochemistry, Biomedical Engineering and Medicine, Case Western Reserve University School of Medicine, Wood W-437, 10900 Euclid Avenue, Cleveland, Ohio, 44106-4935, USA.
E-mail: Michael.Weiss@case.edu

Figure 1: Wild-type insulin hexamer. The A chain (residues A1 - A21) is shown in black and the B chain in blue (residues B1 - B6) or green (residues B7 - B30). Two axial zinc ions (purple; overlaid at center) are coordinated by six histidine side chains (residue B10; white). The structure shown is the R_6 hexamer form characteristic of a pharmaceutical formulation;[150] coordinates were obtained from Protein Databank entry 1EV3.

studies of proteins have ordinarily focused on their native properties, the clinical importance of insulin has motivated detailed study of molecular mechanisms of chemical and physical degradation.[7,8] Such studies foreshadowed the recognition of analogous principles underlying diverse diseases of protein misfolding.[9,10]

Although the insulin monomer (51 amino acids) represents a small motif of protein folding, the Zn hexamer exhibits key features of globular proteins in general: Canonical elements of secondary structure (the α-helix, 3_{10}-helix, β-sheet and β-turn), tertiary organization of a hydrophobic core, specific interfaces for self-assembly, and allosteric regulation through ligand-dependent long-range conformational changes.[11] The crystal structure of insulin underlies modern efforts to optimize its molecular properties for use in the treatment of DM.[12,13] Modification of the insulin molecule to modulate its pharmacokinetic (PK) and pharmacodynamic (PD) properties thus represents a pioneering example of rational protein design.[4,14] Products in current clinical use [Table 1] fall into two classes, rapid-acting analogue formulations intended for bolus injection before meals or use in pumps [Table 1, Panel A] and basal analogue formulations intended for once-a-day injection [Table 1, Panel B]. Because, their PK/PD properties remain suboptimal; however, the 2011 strategic planning document of the United States National Institute of Diabetes Digestive and Kidney Diseases,[15] and the 2011 Meeting Report of the American Diabetes Association,[16] recommended the exploration of novel engineering approaches to better meet clinical goals.

The overall goal of insulin products, singly or in combination, is to help patients with DM to mimic the physiologic pattern of insulin secretion by pancreatic β-cells and so achieve, at least approximately, metabolic homeostasis. The importance of tight glycemic control in Type 1 DM was shown by the classical Diabetes Control and Complications Trial study,[17] and the subsequent Epidemiology of Diabetes Interventions & Complications Study.[18] In long-established Type 2 DM; however, the safety of aggressive glycemic targets is unclear with risks of excess deaths raised by the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study.[19,20] Depending on individual metabolic and clinical features,[21] the United Kingdom Prospective Diabetes Study,[22] and ACCORD subgroup analysis nonetheless support the appropriateness of moderate glycemic targets with avoidance of hypoglycemic episodes.[23] To achieve these clinical objectives, rapid and basal insulin analogues have been designed based on classical crystal structures,[11] and general physicochemical principles.[24] In this review, we seek to integrate such therapeutic objectives with the

Table 1: Current insulin analogues and modes of action[a]		
Analogue	**Modification**	**Mechanism**
A		
Lispro (Humalog®) Eli Lilly and Co	Pro$^{B28}\rightarrow$Lys Lys$^{B29}\rightarrow$Pro	IGF-I-related motif impairs dimerization
Aspart (NovoLog®) Novo-Nordisk	Pro$^{B28}\rightarrow$Asp	Charge repulsion at dimer interface
Glulisine (Apidra®) Sanofi-Aventis	Asn$^{B3}\rightarrow$Lys Lys$^{B29}\rightarrow$Glu	Decreased zinc-free self-association
B		
Glargine (Lantus®) Sanofi-Aventis	Arg^{B31}-Arg^{B32} tag Asp$^{A21}\rightarrow$Gly	Shift in pI to pH 7 leads to isoelectric precipitation on injection
Detemir (Levemir®) Novo-Nordisk	Modification of Lys^{B29} by a tethered fatty acid	Stabilization of hexamer and binding to serum albumin

[a]Panel A describes rapid-acting analogues employed in prandial regimens and in insulin pumps whereas B lists basal insulin analogues with protracted action. Table is reprinted from Berenson *et al.* with permission of the authors.[6]

complementary goal of enhancing the resistance of insulin analogue formulations to degradation above room temperature. Given the global dimensions of DM,[25,26] we anticipate that the next generation of insulin analogues may successfully exploit the physical chemistry of insulin,[27,28] and general principles of protein design,[29,30] to circumvent the complex and costly cold chain of insulin distribution, storage and use in the developing world.[31]

Prandial insulin analogues

Design of insulin analogues has followed the development and application of general principles of protein folding and assembly. These principles were first applied to accelerate the rate of disassembly of Zn hexamers.[32,33] Such efforts posited that more rapid disassembly in the subcutaneous depot would enhance capillary absorption.[4,34] Extensive collections of amino-acid substitutions at subunit interfaces were synthesized and characterized. Whereas, mutational disruption of structure is generally straightforward (in contrast to mutational optimization of structure), favourable substitutions were sought based on three functional criteria: Compatibility with high-affinity binding to the insulin receptor (IR), native biological activity, and feasibility of stable pharmaceutical formulation as defined by national regulatory agencies. There are three such rapid-acting analogues in current use [Table 1, Panel A]; in chronological order of clinical introduction, these are insulin lispro (the active component of Humalog®; Eli Lilly),[35] insulin aspart (Novolog®; Novo-Nordisk),[36,37] and insulin glulisine (Apidra®; Sanofi-Aventis).[38,39] These products have been proven safe and effective in multi-injection regimens,[14,40] and for use in continuous subcutaneous insulin infusion devices (CSII; "insulin pumps").[41] The different molecular changes employed in these three products confer more

rapid insulin absorption, reflecting the many ways that the elegantly crafted assembly of wild-type insulin may be destabilized with maintenance of biological activity. Although current rapid-acting insulin analogue products have met the threshold criteria for chemical and physical stability as set by the United States Food & Drug Administration, these formulations are in general more susceptible to physical and chemical degradation above room temperature than are comparable wild-type formulations. This trade-off in principle poses a dilemma for patients and physicians in the developing world as the therapeutic goal of tight glycemic control may come into conflict with the reality of conditions of daily living in the absence of electrification.

X-ray crystallographic studies of insulin lispro and aspart,[42,43] have revealed native-like assemblies.[2,11] The details of these structures have nonetheless provided insight into their respective mechanisms of rapid action, leading in turn to deeper insight into the structural determinants of classical dimerization.[2,11] Hexamer assembly in each case requires the allosteric binding of phenol or the related ligand meta-cresol, commonly employed for their anti-microbial properties. Such ligands were previously found to induce a large-scale allosteric reorganization of the Zn insulin hexamer [Figure 2] designated the TR transition.[44] Three families of structures have thus been defined: T_6 (the original Hodgkin DC structure of 1969),[1,2] $T_3R_3^f$ (first observed under high-salt conditions as a rhombohedral transformation of Zn insulin crystals),[45] and R_6 (containing six bound ligands per hexamer).[46] Whereas,

the T-state protomer resembles the solution structure of insulin as a monomer in solution,[47-49] in the R-state the B-chain exhibits a change in secondary structure to form an elongated B1 - B19 α-helix; an isolated R-like conformation has not to date been observed. Comparison of these structures by Hodgkin DC et al., provided an informative model for the transmission of conformational change in globular proteins.[11,46,50] The crystal structure of insulin lispro was determined as a $T_3R_3^f$ Zn hexamer containing three bound phenolic ligands [Figure 3a],[42] whereas the structure of insulin aspart was determined as an R_6 hexamer containing six bound ligands [Figure 3b].[43] Comparison of their dimer contacts, including dimer-related anti-parallel β-sheets (residues B24 - B28), revealed subtle distortions [Figures 3c and d].

The dual role of phenolic ligands (i.e., the contingent function of anti-microbial preservatives as allosteric effectors) was essential to stabilize the pharmaceutical formulations of insulins lispro and aspart. Although dissociation of these ligands occurs on the millisecond time scale,[51] the TR transition stabilizes Zn binding,[52] and profoundly retards rates of subunit exchange between hexamers.[53] On subcutaneous injection, the


Figure 2: Exploiting the TR transition in supramolecular protein engineering. (a) Schematic representation of the three types of zinc (Zn) insulin hexamers, designated T_6, $T_3R_3^f$, and R_6. Residues B1 - B8 exhibit a change in secondary structure as shown in Panel B. T-state protomers are otherwise shown in red, and R-state protomers in blue. (b) Corresponding ribbon representation of wild-type crystal structures. Axial Zn ions are shown in purple. Coordinates were obtained from protein databank entries 4INS, 1TRZ, and 1ZNJ, respectively. This figure is reprinted by Wan ZL et al.,[151] with permission of the authors.

Figure 3: Prandial analogues. (a) Insulin lispro as $T_3R_3^f$ hexamer (PDB entry 1LPH). (A and B) chains in T-state are light and dark red; R^f state, light and dark blue. Zinc ions are purple spheres. (b) Aspart as R_6 hexamer (PDB entry 1ZEG). (A and B) chains are light and dark blue. (c and d) Dimer contacts showing B24 - B28 and inter-strand hydrogen bonds (dotted lines). (c) Insulin lispro versus wild-type $T_3R_3^f$ hexamer (component dimers; 1TRZ). (A and B) chains of wild type are light and dark gray. (d) Insulin aspart versus wild-type R_6 hexamer (component dimers; 1ZNJ); wild-type shading is as in C. Figure is from Berenson et al.[6]

ligands presumably diffuse from the injected insulin depot, entering cellular membranes. The unliganded hexamers then rapidly disassemble, facilitating capillary absorption.[4,34] How these mechanisms of assembly and disassembly differ from those of wild-type insulin is not well-understood, but may be pertinent to their increased susceptibility to thermal degradation. Although wild-type insulin forms monodisperse solutions of Zn hexamers in the presence or absence of phenolic ligands, ligand binding is required for monodisperse hexamer assembly of the analogues. Because, the binding sites are distant from the amino-acid substitutions at positions B28 and/or B29, it is not known whether the structural communication occurs between these sites or whether such ligand-dependent assembly reflects a purely formal thermodynamic linkage. While inter-strand hydrogen bonds in the R_6 aspart hexamer are similar to those of wild-type insulin in the same crystal form [Figure 3d],[43] corresponding inter-strand hydrogen bonds in the $T_3R^f_3$ lispro hexamer are in part lengthened [Figure 3c], which might contribute to accelerated disassembly.[42] Because, subsequent spectroscopic studies have suggested that the actual structure of insulin lispro in a formulation is R_6 and not $T_3R^f_3$ (based on cobalt models),[54] it is possible that the $T_3R^f_3$ crystal structure represents an intermediate state of the subcutaneous depot on partial dissociation of the phenolic ligands.

Although the original ideas underlying the design of insulin aspart envisaged electrostatic repulsion at the dimer interface,[32] mutagenesis studies highlighted the key role played by the absence of Pro[B28] and so highlighted its implicit contribution to the wild-type interface.[33] This proline, although conserved at this position among vertebrate insulins, had not previously attracted attention, in part because des-tripeptide (B28 - B30)-insulin, des-tetrapeptide (B27 - B30)-insulin, and des-pentapeptide (B26 - B30)-insulin-amide each exhibit native activity.[11,55,56] Comparison of the crystal structures of insulins lispro and aspart with wild-type insulin in corresponding crystal forms demonstrated a local distortion of the dimer interface associated with the absence of Pro[B28]: The wild-type pyrrolidine ring contacts Gly[B23] in the opposite β-turn [Figures 3a and b]. Thus, informed by the structures of the analogues, this perspective highlighted for the first time the importance of the same contact in the wild-type dimer contact [Figure 3c]. This insight exemplifies the power of mutagenesis to decipher wild-type structure-function relationships even after high-resolution crystallographic analysis.

Advances in closed-loop systems in which control of the pump is controlled by an algorithm based on feedback from a continuous glucose monitor,[57,58]

(i.e., "smart" pumps) have highlighted the need for insulin analogues whose absorption is even faster than current products [Table 1, Panel A].[15,16,59,60] Diverse technologies have been considered, including injection-site heating to increase blood flow,[61,62] co-injection of an enzyme (hyaluronidase) to break down connective-tissue barriers,[63] micro-needle patches,[64] needle-free jet injection,[65] and additives (excipients) that might enhance rates of disassembly.[66,67] The diversity of these approaches highlights the clinical need as perceived in affluent societies.[15] Even as, we anticipate that continuing structural analysis of insulin is likely to provide guidance for future design of ultra-fast analogues synergistic with one or more of these approaches,[68,69] the trade-off described above between structural strategies for rapid action and protein stability may further limit the practicality of closed-loop systems in the developing world, especially in indigent communities.

Basal insulin analogues

A complementary therapeutic objective in the treatment of DM is provided by basal insulin analogue formulations.[70] Whereas, fast-acting analogues are essential for the management of Type 1 DM (including CSII pumps[57-59]), basal insulin analogues contribute to glycemic control as part of multi-injection regimens,[71] and are of fundamental importance in Type 2 DM.[72] The latter patients, when controllable by either prandial or basal analogues alone, prefer a basal regimen to its simplicity and reduced association with weight gain.[73] The global need for ultra-stable basal products may exceed that of rapid-acting formulations given the emerging pandemic of the metabolic syndrome and Type 2 DM in the developing world. Such epidemiological trends are particularly pronounced in the Arabian Gulf region,[74] wherein temperatures in excess of 45°C (even as high as 50 - 60°C) are routinely encountered,[75] including during the Hajj (pilgrimage).[76]

Despite the global need for ultra-stable basal insulin analogues, the goal of targeted stabilization of the insulin hexamer poses a more subtle challenge to the protein engineer than does the converse goal of targeted destabilization as pertinent to rapid-acting analogues.[13,77] Evolutionary optimization of insulin and its elegant self-assembly surfaces (conserved among mammalian insulins,[11]) obscures possible structural routes to further improvement. Although pioneering efforts in this direction were anticipated by Dodson EJ et al.,[11,13] design of current products has circumvented such detailed structural analysis. Insulin glargine (the active component of Lantus®; Sanofi-Aventis) exploits isoelectric precipitation, a reversible transition to insolubility that classically occurs between pH 5

and 6 (under which conditions wild-type insulin exhibits little or no net charge).[78,79] This phenomenon is robust to the details of molecular structure. Insulin glargine contains a two-residue basic extension of the B-chain (Arg^{B31} and Arg^{B32}) whose positive charges result in a shift in the isoelectric point to neutrality. Injection of an unbuffered pH 4 formulation; thus, leads to subcutaneous precipitation and in turn protracted absorption.[80] The B-chain extension is disordered and largely removed by endogenous exopeptidases. Lantus® is the most widely-used long-acting insulin currently on the market.[81] Related analogues containing additional basic residues elsewhere in the insulin molecule have also been described, but are not in clinical use.[82] Insulin detemir (the active component of Levemir®; Novo-Nordisk) contains a fatty acyl group attached to the side chain of Lys^{B29}. This prosthetic group mediates binding to serum albumin to provide a circulating depot.[83] Although receptor binding is partially impaired, this decrease in affinity for the insulin receptor (IR) can be overcome by injecting a higher dose (in nanomoles), rendered convenient to patients by a redefinition of units in a U-100 formulation. The tethered moiety serendipitously enhances the stability of hexamers in the subcutaneous depot, further extending its PK properties.[84] Levemir® is nonetheless ordinarily administered twice a day as its duration of action is less prolonged than that of Lantus®.

MECHANISMS OF INSULIN DEGRADATION

Future progress toward the design of ultra-stable rapid-acting and basal insulin analogues requires analysis of molecular mechanisms of physical and chemical degradation at elevated temperatures. Physical degradation refers to an irreversible change in the physical state of the protein with no change in its covalent structure. This process–designated fibrillation – is now appreciated to be a universal property of polypeptides leading to cross-β assembly of linear polymers.[85] Because analogous misfolding underlies diverse human diseases, including Alzheimer's Disease, Parkinson's Disease, systemic amyloidoses and prion-related encephalopathies,[86-88] the mechanism of protein fibrillation is not well-understood and poses a problem of enormous medical significance.[89] Chemical degradation by contrast refers to a change in the covalent structure of the protein. Mechanisms of chemical degradation have been well-characterized: Principal routes involve deamidation of asparagine, transamidation reactions leading to covalent dimers, and disulfide exchange leading to covalent polymers.[90-94] The relative susceptibility of insulin analogues to chemical degradation correlates with their thermodynamic stabilities and propensity to undergo transient conformational excursions.[7]

To limit degradation, insulin formulations are shipped and stored at 4 - 8°C at which temperature shelf-life is 2 years. Physical and chemical degradation accelerates rapidly with increasing temperature, especially above 30°C. Vials, once used, must be kept below 30°C and discarded after 30 days (15 days in the case of diluted solutions of Humalog® or Novalog®). A general principle is that regions of the molecule that are flexible are most susceptible to degradation and as a corollary conditions that damp conformational fluctuations enhance resistance to degradation. Principal mechanisms of chemical degradation are as follows.[90-95]

Hydrolytic reactions

Acid-catalyzed deamidation of Asn^{A21} and base-catalyzed deamidation of Asn^{B3} are the principal hydrolytic products in acidic and neutral solutions, respectively. Deamidation of Asn^{B3} can also lead to the formation of iso-Asp^{B3} with change in main-chain structure. In neutral solutions phenol retards the rate of B3 deamidation by reducing the conformational flexibility of the B1 - B6 segment.[46,90,96] Deamidation products retain essentially native activity and are not associated with adverse immunogenicity. Substitution of A21 (as in insulin glargine) or B3 (as in insulin glulisine, the active component of Apidra®; Sanofi-Aventis) prevents such deamidation.[5]

Formation of covalent dimers and oligomers

Covalent insulin dimers and oligomers are formed by transpeptidation between amine groups on one molecule (predominantly the B1 α-amino group) and side-chain carboxyamide groups on another (in the A chain). All types of formulations are susceptible. Heterodimers also are formed in neutral-protamine Hagedorn (NPH) insulin between insulin and protamine by the same mechanism. B1-mediated transpeptidation can be avoided by blocking its α-amino group as is under investigation in analogues containing B1 adducts with polyethylene glycol or thyronine.[5] Covalent dimerization can also be initiated by reaction of insulin with aldehyde impurities of glycerol; these can be avoided by using glycerol of high purity or omitting glycerol from the formulation.

Formation of disulfide-linked polymers

Disulfide interchange reactions are initiated by cleavage of cystine A7 - B7 by hydrolysis or β-elimination[90]; because intermolecular disulfide exchange requires juxtaposition between disulfide bridges between different molecules. Such polymers are detectable in regular formulations, but not in micro-crystalline formulations (such as NPH formulations). Their formation is 5-10-fold faster at 37°C than at 4°C.[90-95]

The above degradative mechanisms reflect general properties of proteins. There is an additional mechanism of chemical degradation that is unique to classical Ultralente and Lente formulations. Although these long-acting formulations are generally more robust (due to the tight packing and conformational rigidity of the Zn-stabilized rhombohedral crystals).[95] Ultralente and Lente insulins degrade by specific cleavage of the A8 - A9 peptide bond to yield an inactive but immunogenic three-chain species. Remarkably, in this crystal form insulin acts as a specific endoprotease: A Zn-binding site between hexamers in the crystal lattice mimics the active site of a metalloproteinase, activating a solvent-derived hydroxide molecule for nucleophilic attack on the A8 - A9 scissile bond. This mechanism is only of historical interest in light of the limited use of such micro-crystalline suspensions.

In contrast to the well-characterized mechanisms of chemical degradation, how insulin forms fibrils is enigmatic. Such fibrillation poses a significant issue in the production and storage of formulations.[12,97,98] Patients are instructed to inspect vials for signs of precipitation or frosting of the glass, an indication of surface denaturation and fibrillation. Such vials must be discarded. Although rare, obstruction of insulin pumps due to insulin aggregation can be life-threatening for patients with Type 1 DM due to the rapid onset of ketoacidosis.[99,100]

Insulin is a "grandfather" of amyloidogenic proteins. In the late 1920s, it was observed that heating insulin in acidic solutions yielded an inactive precipitate.[101-103] In the 1940s and 1950s Waugh realized that electron microscopy (EM) observable fibrillation precedes precipitation and defined a nucleation-growth mechanism involving three or four insulin monomers.[104-108] Whereas, elevated temperatures are required for the formation of a nucleus, subsequent growth into fibrils can occur at low temperature and is highly cooperative.[109,110] The danger posed by even transient exposure of insulin formulations to elevated temperatures exacerbates the challenges posed by interruptions in the global cold chain of delivery, distribution, and storage in the developing world.

The molecular structure of an insulin proto-filament and mature fibril defines an active field of research. EM studies between 1950 and 1970 defined fibril dimensions and morphological variability.[111-113] Infrared spectra in 1951 first suggested layers of extended β-strands perpendicular to the fibril axis.[114] Raman studies by Yu NT *et al.* in the 1970s demonstrated that fibrillation is accompanied by an α→β conformational change.[115-117] Insulin fibrillation is accompanied by formation of β-sheet,[118] as characterized by cross-β

X-ray diffraction,[119] a general feature of protein fibrils.[89] The molecular basis of fibrillation is poorly understood. Fibrillation is delayed by classical self-association and by osmolytes like sucrose.[120] Fibrillation is promoted by factors that destabilize the classical self-association pathway from monomer → dimer → tetramer → hexamer → higher-order native assemblies, presumably by increasing the availability of the susceptible monomer [Figure 4].[121] Although relative susceptibilities to fibrillation among analogues do not correlate with their global thermodynamic stabilities, fibrillation is also enhanced by partial unfolding of the monomer by a variety of perturbations, including urea, guanidine, co-solvents (such as ethanol), hydrophobic surfaces, stirring, and high temperature.[120] Insulin fibrillation is accelerated under acidic conditions (pH 1.5 - 2.5), presumably due to dissociation of classical oligomers. The kinetics of fibril formation follows a nucleation-elongation process wherein nucleation involves non-native self-assembly of several partially unfolded monomers; elongation is proposed to occur through subsequent addition of monomers. Nucleation and elongation are manifest as a lag period prior to onset of fibrillation, followed by apparent first-order kinetics in a growth period.[122] The structure of the conformationally altered monomer [purple rhombus in Figure 4] and the nature of its interactions to form a nucleus are poorly understood.[123,124] Although five in equivalent structural models of insulin fibrils have been proposed,[121,125-128] no biophysical data are presently available that discriminate between these proposals.

NEXT-GENERATION INSULIN ANALOGUES

Insulin analogues in current clinical use [Table 1] were

Figure 4: Pathway of insulin fibrillation. Native self-assembly (left) protects insulin from fibrillation through sequestration of monomer (triangle).[120-122] Partial unfolding of monomer (rhombus) exposes non-polar surfaces, leading to an amyloidogenic nucleus and fibril (right). Susceptibility of the insulin monomer to conformational distortion may facilitate receptor binding (bottom) and is distinct from the unfolded state (top); the three disulfide bridges tethering the unfolded state are shown in yellow. Figure is adapted from Fink AL *et al.*,[122] and reprinted from Yang Y *et al.*[69]

designed in the 1990's and face patent expiration in upcoming years. Because of their suboptimal PK/PD properties, efforts to develop "the next generation" analogues have focused on strategies to render rapid-acting formulations more rapid; and basal formulations, more prolonged.[6] An example of the latter is provided by insulin degludec, a next-generation basal insulin analogue under clinical investigation by Novo-Nordisk and academic collaborators.[129-132] The mechanism of this acyl-modified insulin analogue exploits supramolecular self-assembly in the subcutaneous depot. Higher-order assembly is triggered by a change in Zn hexamer conformation, itself associated with the release of the bound phenolic preservative. Analogous supramolecular assembly may be made pH dependent (as in Lantus®) through the introduction of novel Zn-binding sites on the surface of insulin.[133] Although such products will presumably meet a threshold level of stability as required by regulatory agencies, the design goals have not focused on the need for ultra-stability as would be desirable in the developing world, especially in regions of Africa, the Middle East, and Asia which are prone to summertime temperatures > 45°C. An active field of investigation, thus focuses on how the above chemical and structural mechanisms of degradation may need to be circumvented through innovative protein design. Present practices in rural areas of Africa and South Asia include the use of traditional clay pots, of limited utility for storage of temperature-sensitive insulin formulations.[134]

Three novel approaches promise to provide a rational basis for design of innovative ultra-stable insulin analogues. The first, based on biophysical analysis of the native state, seeks to define "Achilles' heels" whose conformational distortion underlies formation of an amyloidogenic nucleus. An example of such analysis was provided by ^{13}C-NMR studies of an engineered insulin monomer.[69] This approach exploited an empirical relationship (designated the chemical shift index [CSI]) between C_α and C_β ^{13}C-NMR chemical shifts and elements of secondary structure, such as α-helix and β-sheet.[135,136] Surprisingly, Yang Y et al., observed that the A1 - A8 segment of an insulin monomer, presumed to be α-helical based on crystal structures of insulin dimers and hexamers, exhibits CSI scores indicative of exchange among α-helical and substantially populated non-helical conformations [Figure 5a]. The anomalous attenuation of CSI scores in the A1 - A8 segment correlated with the conformational variability of this segment among multiple independent crystallographic protomers [Figure 5b], suggesting that in each crystal form the α-helix, when considered in detail, is "frozen" in a distinct segmental conformation. Evidence was presented that such segmental instability reflects the presence of multiple β-branched residues


Figure 5: Anomalous dynamics of insulin. (a) Color-coded ribbon model of insulin T state indicating secondary-structural propensities as derived from ^{13}C-secondary chemical shift.[152] The A1-A8 segment of an engineered monomer exhibits chemical shifts suggestive of non-helical conformational fluctuations. A quantitative scale is shown above ribbon. (b) Ribbon model of insulin T-state color coded according to main-chain RMSD values among T-state protomers. Red indicates greatest variability and blue, least variability. Figure is reprinted from Yang Y et al.[69]

in this segment (Ile^{A2}, Val^{A3}, and Thr^{A8}), intrinsically unfavourable to α-helical folding.[137] Although Ile^{A2} and Val^{A3} are required for biological activity,[138] substitution of Thr^{A8} by non-β-branched side chains confers enhanced stability, damps conformational fluctuations, and augments resistance to fibrillation.[69]

The second approach to obtaining analogues resistant to fibrillation at elevated temperatures exploits models of cross-β assembly.[121,125-128] In such models, the distance between the C-terminus of the B-chain and N-terminus of the A-chain (ordinarily in close proximity in the native state) are generally > 30 Å.[139,140] Imposition of a short peptide tether between these termini (5 - 10 residues in length) may therefore restrict the splaying of A and B chains in the fibrillar state. This idea has led to the design of active single-chain insulin analogues with intrinsic resistance to fibrillation [Figure 6a],[68] even on exposure to elevated temperatures for several months.[140] Clinical application of such designs will require optimization of their PK/PD properties as well as assessment of potential carcinogenicity in animal models. Recently, investigators at Novo-Nordisk have generalized this strategy by the introduction of a fourth disulfide bridge between A and B chains of an otherwise standard two-chain analogue [Figure 6b]. Tethering novel cysteines at positions B4 and A10 (sites ordinarily nearby in the native state), this cross-linked molecule retains biological activity and also exhibits marked resistance to fibrillation. The analogue retains competence to form T_6 Zn hexamers, but not the more stable R_6 structures preferred in pharmaceutical formulations. The feasibility of introducing additional disulfide bridges into insulin was motivated by the finding of such non-canonical cysteines within an invertebrate superfamily of insulin-related polypeptides.[141,142]

Figure 6: Novel structural strategies to augment the resistance of insulin to fibrillation. (a) Single-chain insulin analogues contain a foreshortened connecting domain,[68] which imposes a topological barrier to cross-β assembly.[140] (b) Introduction of a fourth disulfide bridge between residues B4 and A10 likewise impedes fibrillation,[153] presumably via an imposition of a covalent distance constraint that is incompatible with cross-β assembly.[139] Such non-canonical modifications may be engineered with retention of biological activity.

CONCLUSION

The discovery of insulin in 1922, a landmark in molecular medicine, elicited its broad and enduring public support of biomedical research in the western world.[143] The pioneering efforts of the late Hodgkin DC[11] and Liang DC (her former student who led the independent studies of the Peking Insulin Structure Group,[144,145]) to decipher the atomic structure of insulin and its conformational repertoire extended over six decades and engaged an international network of laboratories. Given this epic history, it seems remarkable that this small globular protein continues to inspire molecular innovation, motivated by clinical needs in the developed and developing worlds. Patients with DM daily navigate between treatment-related hypoglycemia on one hand and hyperglycemic excursions on the other. Whereas, acute metabolic decompensation (diabetic ketoacidosis in Type 1 DM and hyperosmolar coma in Type 2) imposes short-term risks, chronic episodic hyperglycemic excursions impose baseline long-term risks of microvascular, macrovascular, and neurologic complications. Next-generation insulin analogues in affluent societies seek to enable patients to achieve glycemic targets and at the same time enhance the convenience and safety with which patients can manage their daily lives. Ongoing efforts to develop next-generation ultra-rapid insulin analogue formulations and ultra-flat basal insulin analogue formulations promise to permit patients to mimic with greater precision endogenous mechanisms of hormonal regulation.

Principles of protein dynamics and stability will come to the fore in yet another dimension of the diabetes challenge: The emerging pandemic of DM in the developing world.[146] The structural principles discussed in this review promise to enable design of novel insulin analogues to meet the higher standards of stability appropriate in the developed world. Whereas for patients in affluent western societies thermal degradation of insulin and insulin analogues is uncommon, the majority of patients in the coming decades will be living in the developing world, including regions (such as in the Arabian Gulf) routinely exposed to summertime temperatures > 45°C. In such regions intertwined scientific, technical, and societal challenges are posed by the cold chain of insulin delivery, storage, and use in the absence of refrigeration or a reliable electrical grid.[147-149] The growing prevalence of DM in Saudi Arabia and elsewhere in the Muslim world poses unique challenges given even more extreme temperatures in the Arabian Peninsula,[75] and the medical needs of those fulfilling the pilgrimage of the Hajj, one of the five pillars of Islam.[76] Given this need and its growing scale, we anticipate that third-generation insulin analogues must combine ultra-stability with optimized PK/PD properties. Such efforts are likely to require the present understanding of the native state of insulin to be extended to non-native states, including metastable partial folds and amyloid.[69] At this frontier design of insulin analogues will require the integration of biochemical principles with ancillary technologies, including the emergent perspective of nanotechnology. We anticipate that such a confluence of technologies will enable diabetes patients in both developed and developing worlds to navigate with ever-increasing safety between the Scylla of hyperglycemia and Charybdis of hypoglycemic episodes.

ACKNOWLEDGMENTS

REFERENCES

1. Adams MJ, Blundell TL, Dodson EJ, Dodson GG, Vijayan M, Baker EN, *et al.* Structure of rhombohedral 2 zinc insulin crystals. Nature 1969;224:491-5.

2. Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, *et al.* Atomic positions in rhombohedral 2-zinc insulin crystals. Nature 1971;231:506-11.

3. Dodson G, Steiner D. The role of assembly in insulin's biosynthesis. Curr Opin Struct Biol 1998;8:189-94.

4. Brange J. The new era of biotech insulin analogues. Diabetologia 1997;40 Suppl 2:S48-53.

5. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83.

6. Berenson DF, Weiss AR, Wan ZL, Weiss MA. Insulin analogs for the treatment of diabetes mellitus: Therapeutic applications of protein engineering. Ann N Y Acad Sci 2011;1243:E40-54.

7. Brange J, Langkjoer L. Insulin structure and stability. Pharm Biotechnol 1993;5:315-50.

8. Brange J, Langkjaer L. Insulin formation and delivery. In: Sanders LM, Hendren RW, (eds). Protein Delivery: Physical Systems. New York, NY: Plenum Press; 1997. p. 343-410.

9. Dobson CM. Protein folding and misfolding. Nature 2003;426:884-90.

10. Trivella DB, Bleicher L, Palmieri L de C, Wiggers HJ, Montanari CA, Kelly JW, *et al*. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: Implications to tetramer stability and ligand-binding. J Struct Biol 2010;170:522-31.

11. Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, *et al*. The structure of 2Zn pig insulin crystals at 1.5 A resolution. Philos Trans R Soc Lond B Biol Sci 1988;319:369-456.

12. Brange J, Skelbaek-Pedersen B, Langkjaer L, Damgaard U, Ege H, Havelund S, *et al*. Galenics of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. Berlin: Springer-Verlag; 1987.

13. Dodson GG, Dodson EJ, Turkenburg JP, Bing X. Molecular recognition in insulin assembly. Biochem Soc Trans 1993;21 (Pt 3):609-14.

14. Freeman JS. Insulin analog therapy: Improving the match with physiologic insulin secretion. J Am Osteopath Assoc 2009;109:26-3.

15. NIDDK. Advances and Emerging Opportunities in Diabetes Research: A Strategic Planning Report of the Diabetes Mellitus Interagency Coordinating Committee (DMICC). In: DMIC (ed). Washington, D.C: NIH Publication; 2011.

16. ADA. American Diabetes Association Scientific Sessions 2011. San Diego, California; 2011 June 24-28.

17. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. N Engl J Med 1993; 329:977-86.

18. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, *et al*. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.

19. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, *et al*. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.

20. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation 2010;122:844-6.

21. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001;104:517-29.

22. Nicollerat JA. Implications of the United Kingdom prospective diabetes study (UKPDS) results on patient management. Diabetes Educ 2000;26 Suppl:8-10.

23. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: Implications of recent clinical trials. Ann Intern Med 2011;154:554-9.

24. Creighton TE. Protein Structure: A Practical Approach. Oxford: IRL Press at Oxford University Press; 1997.

25. van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010;17 Suppl 1:S3-8.

26. Farag YM, Gaballa MR. Diabesity: An overview of a rising epidemic. Nephrol Dial Transplant 2011;26:28-35.

27. Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999;35:307-35.

28. Pandyarajan V, Weiss MA. Design of non-standard insulin analogs for the treatment of diabetes mellitus. Curr Diab Rep 2012;12:697-704.

29. Regan L. Protein design: Novel metal-binding sites. Trends Biochem Sci 1995;20:280-5.

30. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. Rational design and engineering of therapeutic proteins. Drug Discov Today 2003;8:212-21.

31. Wirkas T, Toikilik S, Miller N, Morgan C, Clements CJ. A vaccine cold chain freezing study in PNG highlights technology needs for hot climate countries. Vaccine 2007;25:691-7.

32. Brange J, Hansen JF, Havelund S, Melberg SG. Studies of insulin fibrillation process. In: Brunetti P, Waldhäusl WK, (eds). Advanced Models for the Therapy of Insulin -Dependent Diabeses. New York: Raven Press; 1987. p. 85-90.

33. Brems DN, Alter LA, Beckage MJ, Chance RE, DiMarchi RD, Green LK, *et al*. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992;5:527-33.

34. DeFelippis MR, Chance RE, Frank BH. Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst 2001;18:201-64.

35. DiMarchi RD, Chance RE, Long HB, Shields JE, Slieker LJ. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. Horm Res 1994;41 Suppl 2:93-6.

36. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: Human insulin B28Asp. Diabet Med 1993;10:535-9.

37. Owens D, Vora J. Insulin aspart: A review. Expert Opin Drug Metab Toxicol 2006;2:793-804.

38. Barlocco D. Insulin glulisine. Aventis Pharma. Curr Opin Investig Drugs 2003;4:1240-4.

39. Helms KL, Kelley KW. Insulin glulisine: An evaluation of its pharmacodynamic properties and clinical application. Ann Pharmacother 2009;43:658-68.

40. Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus. Endocr Pract 2010;16:486-505.

41. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-6.

42. Ciszak E, Beals JM, Frank BH, Baker JC, Carter ND, Smith GD. Role of C-terminal B-chain residues in insulin assembly: The structure of hexameric LysB28ProB29-human insulin. Structure 1995;3:615-22.

43. Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro—> Asp insulin analogues. Biochemistry 1998;37:11516-23.

44. Brader ML, Dunn MF. Insulin hexamers: New conformations and applications. Trends Biochem Sci 1991;16:341-5.

45. Bentley G, Dodson E, Dodson G, Hodgkin D, Mercola D. Structure of insulin in 4-zinc insulin. Nature 1976;261:166-8.

46. Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, *et al*. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature 1989;338:594-6.

47. Hua QX, Shoelson SE, Kochoyan M, Weiss MA. Receptor binding redefined by a structural switch in a mutant human insulin. Nature 1991;354:238-41.

48. Hua QX, Hu SQ, Frank BH, Jia W, Chu YC, Wang SH, *et al*. Mapping the functional surface of insulin by design: Structure and function of a novel A-chain analogue. J Mol Biol 1996;264:390-403.

49. Olsen HB, Ludvigsen S, Kaarsholm NC. Solution structure of an engineered insulin monomer at neutral pH. Biochemistry 1996;35:8836-45.

50. Chothia C, Lesk AM, Dodson GG, Hodgkin DC. Transmission of conformational change in insulin. Nature 1983;302:500-5.

51. Jacoby E, Krüger P, Schlitter J, Röper D, Wollmer A. Simulation of a complex protein structural change: The $T < - > R$ transition in the insulin hexamer. Protein Eng 1996;9:113-25.

52. Brader ML, Kaarsholm NC, Lee RW, Dunn MF. Characterization of the R-state insulin hexamer and its derivatives. The hexamer is stabilized by heterotropic ligand binding interactions. Biochemistry 1991;30:6636-45.

53. Hassiepen U, Federwisch M, Mülders T, Wollmer A. The lifetime of insulin hexamers. Biophys J 1999;77:1638-54.

54. Richards JP, Stickelmeyer MP, Flora DB, Chance RE, Frank BH, DeFelippis MR. Self-association properties of monomeric insulin analogs under formulation conditions. Pharm Res 1998;15:1434-41.

55. Cosmatos A, Ferderigos N, Katsoyannis PG. Chemical synthesis of des(tetrapeptide B27 – 30), Tyr(NH2)26-B and des(pentapeptide B26 – 30), Phe(NH2)25-B bovine insulins. Int J Pept Protein Res 1979;14:457-71.

56. Fischer WH, Saunders D, Brandenburg D, Wollmer A, Zahn H. A shortened insulin with full *in vitro* potency. Biol Chem Hoppe Seyler 1985;366:521-5.

57. Elleri D, Dunger DB, Hovorka R. Closed-loop insulin delivery for treatment of type 1 diabetes. BMC Med 2011;9:120.

58. Schaepelynck P, Darmon P, Molines L, Jannot-Lamotte MF, Treglia C, Raccah D. Advances in pump technology: Insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab 2011;37 Suppl 4:S85-93.

59. Brown L, Edelman ER. Optimal control of blood glucose: The diabetic patient or the machine? Sci Transl Med 2010;2:27ps18.

60. Scutcher M, Vasilakis-Scaramozza C, Sullivan K. Diabetic complications. In: Vital Biopharmaceutical Insights and Analytics for Experts from Experts. Burlington, Mass: Decision Resources Group Co.; 2011.

61. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009;31:980-7.

62. Jakobsen LA, Jensen A, Larsen LE, Sørensen MR, Hoeck HC, Arendt-Nielsen L, *et al*. Effect of cutaneous blood flow on absorption of insulin: A methodological study in healthy male volunteers. Int J Physiol Pathophysiol Pharmacol 2011;3:257-65.

63. Vaughn DE, Muchmore DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: Experience with subcutaneous injection and continuous infusion. Endocr Pract 2011;17:914-21.

64. Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, *et al*. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther 2011;13:435-42.

65. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011;34:1804-8.

66. Hompesch M, McManus L, Pohl R, Simms P, Pfützner A, Bülow E, *et al*. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol 2008;2:568-71.

67. Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, *et al*. U-100, pH-Neutral formulation of VIAject(®): Faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 2012;14:222-7.

68. Hua QX, Nakagawa SH, Jia W, Huang K, Phillips NB, Hu SQ, *et al*. Design of an active ultrastable single-chain insulin analog: Synthesis, structure, and therapeutic implications. J Biol Chem 2008;283:14703-16.

69. Yang Y, Petkova A, Huang K, Xu B, Hua QX, Ye IJ, *et al*. An Achilles' heel in an amyloidogenic protein and its repair: Insulin fibrillation and therapeutic design. J Biol Chem 2010;285:10806-21.

70. Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ. Long-acting insulin analogs: A review of "real-world" effectiveness in patients with type 2 diabetes. Curr Diabetes Rev 2011;7:61-74.

71. King AB, Armstrong DU. Basal bolus dosing: A clinical experience. Curr Diabetes Rev 2005;1:215-20.

72. Baxter MA. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Acta Diabetol 2008;45:253-68.

73. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis. Diabetes Obes Metab 2011;13:1008-19.

74. Bahijri SM, Al Raddadi RM. The importance of local criteria in the diagnosis of metabolic syndrome in Saudi Arabia. Ther Adv Endocrinol Metab 2013;4:51-9.

75. Noweir MH, Bafail AO. Study of summer heat exposure at the ground services operations of a main international airport in Saudi Arabia. Environ Monit Assess 2008;145:103-11.

76. Noweir MH, Bafail AO, Jomoah IM. Study of heat exposure during Hajj (pilgrimage). Environ Monit Assess 2008;147:279-95.

77. Markussen J, Diers I, Hougaard P, Langkjaer L, Norris K, Snel L, *et al*. Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. Protein Eng 1988;2:157-66.

78. Owens DR, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002;56:460-6.

79. Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin Glargine: A review 8 years after its introduction. Expert Opin Pharmacother 2009;10:705-18.

80. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.

81. Aggarwal SR. What's fueling the biotech engine-2011 to 2012.

Nat Biotechnol 2012;30:1191-7.

82. Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang L, *et al*. pI-shifted insulin analogs with extended *in vivo* time action and favorable receptor selectivity. Peptides 2007;28:935-48.

83. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, *et al*. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-504.

84. Whittingham JL, Jonassen I, Havelund S, Roberts SM, Dodson EJ, Verma CS, *et al*. Crystallographic and solution studies of N-lithocholyl insulin: A new generation of prolonged-acting human insulins. Biochemistry 2004;43:5987-95.

85. Dobson CM, Karplus M. The fundamentals of protein folding: Bringing together theory and experiment. Curr Opin Struct Biol 1999;9:92-101.

86. Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng 2002;4:155-74.

87. Dalsgaard NJ. Prion diseases. An overview. APMIS 2002;110:3-13.

88. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: Insights from animal models. Nat Rev Neurosci 2003;4:727-38.

89. Sipe JD, Cohen AS. Review: History of the amyloid fibril. J Struct Biol 2000;130:88-9.

90. Brange J, Langkjaer L, Havelund S, Vølund A. Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res 1992;9:715-26.

91. Brange J, Havelund S, Hougaard P. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res 1992;9:727-34.

92. Brange J, Langkjaer L. Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. Acta Pharm Nord 1992;4:149-58.

93. Brange J. Chemical stability of insulin. 4. Mechanisms and kinetics of chemical transformations in pharmaceutical formulation. Acta Pharm Nord 1992;4:209-22.

94. Brange J, Hallund O, Sørensen E. Chemical stability of insulin. 5. Isolation, characterization and identification of insulin transformation products. Acta Pharm Nord 1992;4:223-32.

95. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci 1997;86:517-25.

96. Wollmer A, Rannefeld B, Johansen BR, Hejnaes KR, Balschmidt P, Hansen FB. Phenol-promoted structural transformation of insulin in solution. Biol Chem Hoppe Seyler 1987;368:903-11.

97. Benson EA, Benson JW Jr, Fredlund PN, Mecklenburg RS, Metz R. Flocculation and loss of potency of human NPH insulin. Diabetes Care 1988;11:563-6.

98. Brange J, Langkjaer L. Insulin formulation and delivery. Pharm Biotechnol 1997;10:343-409.

99. Lindenbaum C, Menzin A, Ludmir J. Diabetic ketoacidosis in pregnancy resulting from insulin pump failure. A case report. J Reprod Med 1993;38:306-8.

100. Dunn FL, Nathan DM, Scavini M, Selam JL, Wingrove TG. Long-term therapy of IDDM with an implantable insulin pump. The implantable insulin pump trial study group. Diabetes Care 1997;20:59-63.

101. Blatherwick NR, Bischoff F, Maxwell LC, Berger J, Sahyun M. Studies on insulin. J Biol Chem 1927;72:57-89.

102. Krogh A, Hemmingsen AM. The destructive action of heat on insulin solutions. Biochem J 1928;22:1231-8.

103. Bischoff F, Sahyun M. Denaturation of insulin protein by concentrated sulfuric acid. J Biol Chem 1929;81:167-73.

104. Langmuir I, Waugh DF. Pressure-soluble and pressure displaced components of monolayers of native and denatured proteins. J Am Chem Soc 1940;62:2771-93.

105. Waugh DF. The properties of protein fibers produced. Reversibly from soluble protein molecules. Am J Physiol 1941;133:P484-5.

106. Waugh DF. The linkage of corpuscular protein molecules. I. A fibrous modification on insulin. J Am Chem Soc 1944;66:663.

107. Waugh DF. A fibrous modification of insulin. I. The heat precipitate of insulin. J Am Chem Soc 1946;68:247-50.

108. Waugh DF. Reactions involved in insulin fibril formation. Fed Proc 1946;5:111.

109. Waugh DF, Wilhelmson DF, Commerford SL, Sackler ML. Studies of the nucleation and growth of selected types of insulin fibrils. J Am Chem Soc 1953;75:2592-600.

110. Waugh DF. A mechanism for the formation of fibrils from protein molecules. J Cell Physiol Suppl 1957;49:145-64.

111. Farrant JL, Mercer EH. Electron microscopical observations of fibrous insulin. Biochim Biophys Acta 1952;8:355-9.

112. Kung TH, Tsao TC. The ultrastructure of insulin fibrils. Sci Sin 1964;13:471-8.

113. Glenner GG, Eanes ED, Bladen HA, Linke RP, Termine JD. Beta-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils. J Histochem Cytochem 1974;22:1141-58.

114. Ambrose EJ, Elliott A. Infra-red spectroscopic studies of globular protein structure. Proc R Soc Lond A Math Phys Sci 1951;208:75-90.

115. Yu NT, Liu CS, O'Shea DC. Laser Raman spectroscopy and the conformation of insulin and proinsulin. J Mol Biol 1972;70:117-32.

116. Yu NT, Liu CS. Laser Raman spectra of native and denatured insulin in the solid state. J Am Chem Soc 1972;94:3250-1.

117. Yu NT, Jo BH, Chang RC, Huber JD. Single-crystal Raman spectra of native insulin. Structures of insulin fibrils, glucagon fibrils, and intact calf lens. Arch Biochem Biophys 1974;160:614-22.

118. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci 2000;9:1960-7.

119. Koltun WL, Waugh DF, Bear RS. An X-ray diffraction investigation of selected types of insulin fibrils. J Am Chem Soc 1954;76:413-7.

120. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, *et al*. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 2001;40:6036-46.

121. Brange J, Dodson GG, Edwards DJ, Holden PH, Whittingham JL. A model of insulin fibrils derived from the x-ray crystal structure of a monomeric insulin (despentapeptide insulin). Proteins 1997;27:507-16.

122. Nielsen L, Frokjaer S, Brange J, Uversky VN, Fink AL. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 2001;40:8397-409.

123. Nettleton EJ, Tito P, Sunde M, Bouchard M, Dobson CM, Robinson CV. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Biophys J 2000;79:1053-65.

124. Tito P, Nettleton EJ, Robinson CV. Dissecting the hydrogen exchange properties of insulin under amyloid fibril forming conditions: A site-specific investigation by mass spectrometry. J Mol Biol 2000;303:267-78.

125. Jiménez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci U S A 2002;99:9196-201.

126. Choi JH, May BC, Wille H, Cohen FE. Molecular modeling of the misfolded insulin subunit and amyloid fibril. Biophys J 2009;97:3187-95.

127. Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D. Molecular basis for insulin fibril assembly. Proc Natl Acad Sci U S A 2009;106:18990-5.

128. Babenko V, Dzwolak W. Amino acid sequence determinants in self-assembly of insulin chiral amyloid superstructures: Role of C-terminus of B-chain in association of fibrils. FEBS Lett 2013;587:625-30.

129. Markussen J, Jonassen I, Havelund S, Brandt J, Kurtzhals P, Hansen PH, et al. Inventors; insulin derivatives. U. S. A. Patent 6,620,780. Sept. 16 2003.

130. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: A 16-week, randomised, open-label, phase 2 trial. Lancet 2011;377:924-31.

131. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011;34:661-5.

132. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: A randomized, controlled trial. Diabetes Care 2011;34:669-74.

133. Phillips NB, Wan ZL, Whittaker L, Hu SQ, Huang K, Hua QX, et al. Supramolecular protein engineering: Design of zinc-stapled insulin hexamers as a long acting depot. J Biol Chem 2010;285:11755-9.

134. Gill G, Price C, English P, Eriksson-Lee J. Traditional clay pots as storage containers for insulin in hot climates. Trop Doct 2002;32:237-8.

135. Wishart DS, Sykes BD. The 13C chemical-shift index: A simple method for the identification of protein secondary structure using 13C chemical-shift data. J Biomol NMR 1994;4:171-80.

136. Wishart DS, Sykes BD, Richards FM. The chemical shift index: A fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry 1992;31:1647-51.

137. O'Neil KT, DeGrado WF. A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 1990;250:646-51.

138. Nakagawa SH, Tager HS. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions. Biochemistry 1992;31:3204-14.

139. Huang K, Dong J, Phillips NB, Carey PR, Weiss MA. Proinsulin is refractory to protein fibrillation: Topological protection of a precursor protein from cross-beta assembly. J Biol Chem 2005;280:42345-55.

140. Phillips NB, Whittaker J, Ismail-Beigi F, Weiss MA. Insulin fibrillation and protein design: Topological resistance of single-chain analogs to thermal degradation with application to a pump reservoir. J Diabetes Sci Technol 2012;6:277-88.

141. Pierce SB, Costa M, Wisotzkey R, Devadhar S, Homburger SA, Buchman AR, et al. Regulation of DAF-2 receptor signaling by human insulin and ins-1, a member of the unusually large and diverse C. elegans insulin gene family. Genes Dev 2001;15:672-86.

142. Hua QX, Nakagawa SH, Wilken J, Ramos RR, Jia W, Bass J, et al. A divergent INS protein in Caenorhabditis elegans structurally resembles human insulin and activates the human insulin receptor. Genes Dev 2003;17:826-31.

143. Bliss M. The Discovery of Insulin: Twenty-fifth Anniversary Edition. Chicago: University of Chicago Press; 2007.

144. Rao Z. History of protein crystallography in China. Philos Trans R Soc Lond B Biol Sci 2007;362:1035-42.

145. Hua Q. Insulin: A small protein with a long journey. Protein Cell 2010;1:537-51.

146. Hua QX, Jia W, Weiss MA. Conformational dynamics of insulin. Front Endocrinol (Lausanne) 2011;2:48.

147. Osei K. Global epidemic of type 2 diabetes: Implications for developing countries. Ethn Dis 2003;13:S102-6.

148. Osei K, Schuster DP, Amoah AG, Owusu SK. Diabetes in Africa. Pathogenesis of type 1 and type 2 diabetes mellitus in sub-Saharan Africa: Implications for transitional populations. J Cardiovasc Risk 2003;10:85-96.

149. Lefèbvre P, Pierson A. The global challenge of diabetes. World Hosp Health Serv 2004;40:37-40, 42.

150. Derewenda U, Derewenda Z, Dodson GG, Hubbard RE, Korber F. Molecular structure of insulin: The insulin monomer and its assembly. Br Med Bull 1989;45:4-18.

151. Wan ZL, Huang K, Hu SQ, Whittaker J, Weiss MA. The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition. J Biol Chem 2008;283:21198-210.

152. Marsh JA, Singh VK, Jia Z, Forman-Kay JD. Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: Implications for fibrillation. Protein Sci 2006;15:2795-804.

153. Vinther TN, Norrman M, Ribel U, Huus K, Schlein M, Steensgaard DB, et al. Insulin analog with additional disulfide bond has increased stability and preserved activity. Protein Sci 2013;22:296-305.